MX2020004071A - Derivados de aztreonam y usos de los mismos. - Google Patents

Derivados de aztreonam y usos de los mismos.

Info

Publication number
MX2020004071A
MX2020004071A MX2020004071A MX2020004071A MX2020004071A MX 2020004071 A MX2020004071 A MX 2020004071A MX 2020004071 A MX2020004071 A MX 2020004071A MX 2020004071 A MX2020004071 A MX 2020004071A MX 2020004071 A MX2020004071 A MX 2020004071A
Authority
MX
Mexico
Prior art keywords
aztreonam derivatives
aztreonam
derivatives
empty
Prior art date
Application number
MX2020004071A
Other languages
English (en)
Inventor
John Freund
Eric M Gordon
Matthew A J Duncton
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of MX2020004071A publication Critical patent/MX2020004071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/79—Halides of sulfonic acids having halosulfonyl groups bound to acyclic carbon atoms
    • C07C309/82—Halides of sulfonic acids having halosulfonyl groups bound to acyclic carbon atoms of a carbon skeleton substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Se describen en la presente derivados de aztreonam, métodos terapéuticos de uso de los derivados de aztreonam, particulaimente en combinación con inhibidores de ß-Iactamasa, y composiciones farmacéuticas de los mismos. Los derivados de aztreonam pueden administrarse oralmente para proporcionar aztreonam biodisponible oralmente.
MX2020004071A 2017-10-02 2018-10-01 Derivados de aztreonam y usos de los mismos. MX2020004071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566909P 2017-10-02 2017-10-02
PCT/US2018/053778 WO2019070595A1 (en) 2017-10-02 2018-10-01 AZTREONAM DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020004071A true MX2020004071A (es) 2020-07-28

Family

ID=63963503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004071A MX2020004071A (es) 2017-10-02 2018-10-01 Derivados de aztreonam y usos de los mismos.

Country Status (12)

Country Link
US (3) US10280161B2 (es)
EP (1) EP3676247B8 (es)
JP (1) JP6991345B2 (es)
KR (1) KR102455390B1 (es)
CN (1) CN111448182A (es)
AU (1) AU2018345321B2 (es)
BR (1) BR112020006594A2 (es)
CA (1) CA3077474A1 (es)
IL (1) IL273571A (es)
MX (1) MX2020004071A (es)
SG (1) SG11202002300QA (es)
WO (1) WO2019070595A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.
ES2991492T3 (es) 2018-10-01 2024-12-03 Arixa Pharmaceuticals Inc Derivados de relebactam y usos de los mismos
US11008321B2 (en) 2019-03-12 2021-05-18 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
WO2020219258A1 (en) * 2019-04-25 2020-10-29 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
EP4021443A1 (en) 2019-08-29 2022-07-06 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
CN112047840A (zh) * 2020-08-31 2020-12-08 山东药品食品职业学院 一种7-溴-2,2-二甲基庚酸乙酯的合成方法及合成得到的产品
CN112661716A (zh) * 2020-12-31 2021-04-16 山东金城柯瑞化学有限公司 一种三苯甲基氨噻肟酸的制备方法
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN118561730B (zh) * 2024-07-03 2024-11-22 北京世纪迈劲生物科技有限公司 一种氨曲南主环中间体的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
US4775670A (en) * 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
GB2113997B (en) * 1982-02-02 1985-07-03 Leo Pharm Prod Ltd Synergistic antibacterial compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4652651A (en) 1983-05-31 1987-03-24 Hoffmann-La Roche Inc. Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid intermediates via catalytic ester cleavage
JPS60222480A (ja) * 1984-04-20 1985-11-07 Kanegafuchi Chem Ind Co Ltd ２−アゼチジノン−１−スルホン酸誘導体
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
CN101171251A (zh) * 2005-05-09 2008-04-30 西科尔公司 氨曲南的制备方法
WO2007083187A2 (en) 2006-01-16 2007-07-26 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of monobactam antibiotic
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200924746A (en) 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
CN101514200B (zh) * 2009-03-31 2011-02-16 海南美大制药有限公司 一种氨曲南化合物及其新制法
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
RS59255B1 (sr) 2010-04-20 2019-10-31 Fujifilm Toyama Chemical Co Ltd Derivat hidroksaminske kiseline
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
CN102127068B (zh) * 2010-12-31 2012-08-29 山西普德药业股份有限公司 一种合成氨曲南化合物的方法
AR086590A1 (es) 2011-05-30 2014-01-08 Sumitomo Chemical Co Compuestos de ciclohexanona y herbicidas que los comprenden
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103232449B (zh) * 2013-05-08 2014-04-09 四川省惠达药业有限公司 一种氨曲南化合物、其制备方法及其药物组合物
HUE042134T2 (hu) * 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
CA2960949A1 (en) 2014-09-12 2016-03-17 Tatsuya Honda Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
CN106794162A (zh) 2014-09-12 2017-05-31 富山化学工业株式会社 组合使用新的异羟肟酸衍生物和抗菌性物质的方法
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CA2984024A1 (en) 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2020004071A (es) * 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.

Also Published As

Publication number Publication date
EP3676247B8 (en) 2023-04-12
AU2018345321B2 (en) 2021-05-20
US20210009580A1 (en) 2021-01-14
US20190211006A1 (en) 2019-07-11
BR112020006594A2 (pt) 2020-12-15
SG11202002300QA (en) 2020-04-29
CN111448182A (zh) 2020-07-24
WO2019070595A1 (en) 2019-04-11
JP2020536122A (ja) 2020-12-10
KR102455390B1 (ko) 2022-10-17
EP3676247B1 (en) 2023-03-08
EP3676247A1 (en) 2020-07-08
KR20200060490A (ko) 2020-05-29
JP6991345B2 (ja) 2022-01-12
AU2018345321A1 (en) 2020-04-16
US10815228B2 (en) 2020-10-27
CA3077474A1 (en) 2019-04-11
US10280161B2 (en) 2019-05-07
IL273571A (en) 2020-05-31
US20190100516A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2020004287A (es) Procesamiento de biomasa.
MX2020003760A (es) Formulaciones de niraparib.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
MX2020014120A (es) Agonistas parciales del receptor de insulina.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
GEP20217239B (en) Pharmaceutical composition
MX2020004424A (es) Formulacion aerosolizable.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
MX2020004241A (es) Conector y montaje de conector.
IL273571A (en) Azterion derivatives and their uses
MX2020004227A (es) Estructura plana termicamente fijable.
AU201714352S (en) Ratchet Handle
AU201714353S (en) Ratchet Handle
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
MX2023006458A (es) Oligosacaridos inmunomoduladores.
MX2019015167A (es) Farmacos antivirales.
MX2020003616A (es) Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2020003768A (es) Composiciones acuosas herbicidas y metodos para usar las mismas.
MX2020004008A (es) Caja de carton y plantilla para la misma.
MX2020002908A (es) Composicion acuosa de polimeros.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof